covid-19 Government infection Coronavirus

Takeda teams up with plasma firms for Covid-19 hyperimmune therapy

Reading now: 141
www.pharmaceutical-technology.com

Takeda Pharmaceutical and its partner CSL Behring have teamed up with plasma companies Biotest, BPL, LFB and Octapharma to develop a hyperimmune therapy for Covid-19.

The partners aim to immediately create an unbranded, plasma-derived polyclonal hyperimmune immunoglobulin therapy to treat serious complications associated with the novel coronavirus infection.

As part of the collaboration, the companies will leverage their expertise and ongoing work. Partnerships of experts under the alliance will form for plasma collections, clinical trial development and manufacturing activities.

Takeda hyperimmune therapy requires plasma donation from several people who recovered from Covid-19 and have coronavirus antibodies in their blood.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA